Replimune receives FDA acceptance of resubmitted BLA for RP1 in advanced melanoma
Replimune (NASDAQ:REPL) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.






-2-640x358.webp&w=3840&q=75)



